SEC Form 4 · accession 0001209191-19-014215
TANDEM DIABETES CARE INC · TNDM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John F Sheridan
Officer — EVP, CHIEF OPERATING OFFICER
Period of report
Feb 25, 2019
Accepted (ET)
Feb 27, 2019 · 6:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438133
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 27, 2019 | M | 18,333 | $2.59 | A | 18,999 | D | |
| Common StockF1 | Feb 27, 2019 | M | 1,667 | $9.00 | A | 20,666 | D | |
| Common StockF2 | Feb 27, 2019 | S | 16,200 | $61.91 | D | 4,466 | D | |
| Common StockF3 | Feb 27, 2019 | S | 3,800 | $62.53 | D | 666 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common StockF4,F5,F6 | $48.36 | Feb 25, 2019 | A | 105,000 | A | — | — | Common Stock | 105,000 | 105,000 | D |
| Common StockF7 | $2.59 | Feb 27, 2019 | M | 18,333 | D | — | Dec 1, 2027 | Common Stock | 18,333 | 41,667 | D |
| Common StockF8 | $9.00 | Feb 27, 2019 | M | 1,667 | D | — | May 17, 2027 | Common Stock | 1,667 | 8,333 | D |
Explanation of responses
- F1Represents shares of common stock received upon exercise of a stock option award.
- F2The price reported reflects the weighted average price. The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2018, in multiple transactions at prices ranging from $61.50 to $62.50.
- F3The price reported reflects the weighted average price. The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2018, in multiple transactions at prices ranging from $62.51 to $62.62.
- F4Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. The grant is contingent upon future stockholder approval of an increase in the number of shares reserved for issuance under the 2013 Stock Incentive Plan.
- F5The option shall vest as to twenty-five percent (25%) of the underlying shares on 2/25/2020, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter
- F6The expiration date for these options is ten (10) years from the date of grant.
- F7Fifty percent (50%) of the underlying shares subject to the option vested on 12/1/2018, and the remaining shares shall vest in twelve (12) equal monthly installments thereafter
- F8Twenty five percent (25%) of the underlying shares subject to the option vested on 05/17/2018, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter